PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsZurex Pharma
Zurex Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
ZuragardFenofibrate2019-04-262024-2033
Hypercholesterolemia
,
Coronary artery disease
,
Dyslipidemias
,
Hypertriglyceridemia
,
Hyperlipoproteinemias
,
Periodontal diseases
,
Infectious skin diseases
,
Gram-negative bacterial infections
,
Oral candidiasis
,
Gram-positive bacterial infections
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Fenofibrate
surgical wound infection
Methylthioninium chloride
surgical wound infection
Sodium chloride
healthy volunteers/patients
,
cardiovascular abnormalities
,
thalassemia
,
amyotrophic lateral sclerosis
,
motor neuron disease
,
sclerosis
,
type 2 diabetes mellitus
,
hypertriglyceridemia
,
fatty liver
,
chronic kidney failure
,
kidney diseases
,
cardiovascular diseases
,
hyperlipidemias
,
macular degeneration
,
geographic atrophy
,
atrophy
,
hyperlipoproteinemias
,
liver diseases
,
diabetes mellitus
,
non-alcoholic fatty liver disease
,
covid-19
,
metabolic diseases
,
dyslipidemias
,
metabolic syndrome
,
metabolic brain diseases
,
lipid metabolism disorders
,
hepatitis b
,
chronic hepatitis b
,
hepatitis
,
chronic hepatitis
,
hepatitis a
,
hypercholesterolemia
,
coronary disease
,
coronary artery disease
,
myocardial ischemia
,
heart diseases
Riboprine
surgical wound infection
Zuraprep
surgical wound infection
Chloraprep
surgical wound infection
Corsodyl
surgical wound infection
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use